Solana Company Q1 FY2023 Earnings Call

· Earnings call transcript and AI-powered summary

  • Clinical & Commercial Update: Q1 2023 marks one year of commercial availability of PoNS Therapy in the U.S. targeting balance and gait impairments in MS patients. Rollout continues across more therapists and physicians, supported by a new e-commerce platform launched via ponstherapy.com.
  • Patient Access: PoNS currently runs on a cash-pay basis at a discounted price of $14,500 (down from a $25,700 list price). To support access, the Patient Therapy Access Program (PTAP) offers an 85% discount to qualified patients, extended through June 2023.
  • E-commerce Expansion: Online platform allows remote health evaluations, prescription fulfillment, and device delivery. First deliveries occurred in January 2023; adoption has been strong, with ongoing optimization of the patient journey.
  • Therapist Training: Online portal for physical therapist training continues to accelerate onboarding of professionals in both the U.S. and Canada, matching patient demand with therapist availability.
  • Clinical Data Highlights:
    • Canadian stroke data shows 70% of patients improved gait; 28% reduced fall risk—a major leap over the 1–3% improvement from physical therapy alone.
    • 74% of TBI patients (Canada) had significant balance improvements.

Continue Reading

Unlock the full AI-powered summary with key highlights, financial performance, and analyst Q&A.

Upgrade to Professional
Operator: Good day, and thank you for standing by. Welcome to the Helius Medical Technologies, Inc. Quarter One 2023 Earnings Conference Call. At this time, all participants are in listen-only mode. After the speakers’ presentation, there will be a question-and-answer session [Operator Instructions] Please be advised that today’s conference is being recorded. I would now like to hand the conference over to your speaker today, Michelle Bilski of In-Site Communications. The line is now yours. Michelle Bilski: Thank you, Gerald. Welcome to the first quarter 2023 earnings conference call for Helius Medical Technologies. This is Michelle Bilski of In-Site Communications, Investor Relations for Helius. With me on today’s call are Dane Andreeff, Helius Medical’s President and Chief Executive Officer; and Jeff Mathiesen, Chief Financial Officer. At this time, all participants have been placed in a listen-only mode. Please note that this call is being recorded, and access to the webcast can be obtained through the Investors section of Helius website at www.heliusmedical.com. Before we begin, I would like to remind everyone that our remarks and responses to your questions today may contain forward-looking statements that are based on the current expectations of management. These forward-looking statements involve inherent risks and uncertainties that could cause actual results to differ materially from those indicated, including those identified in the Risk Factors section of our most

Continue Reading

Unlock the full earnings call transcript with speaker labels and formatted dialogue.

Upgrade to Professional